$ALLO
Allogene Therapeutics Inc ($ALLO )
$1.23
-$0.01(-1.21%)Today
1D5D1M6MYTD1Y5Ymax
Open1.22
Volume1.1M
Day Low1.20
Day High1.25
Year Low0.86
Year High3.78
📊 ALLO (Allogene Therapeutics) — Latest Analysis
What is ALLO?
It’s a biotech company focused on allogeneic CAR-T therapy, meaning “off-the-shelf” cancer-fighting cells.
Their pipeline includes treatments for large B-cell lymphoma, autoimmune diseases, and kidney cancer.
🔍 Key Strengths & Risks
Strengths:
Strong cash position: ~$277 million, giving them runway until second half of 2027.
Big clinical catalysts coming:
ALPHA3 trial for lymphoma (phase 2) – futility readout expected in H1 2026.
ALLO-329 trial (autoimmune) – early data expected H1 2026.
Risks:
Safety concerns: There was a Grade 5 event in one of the trials, which raises red flags.
Big losses: They’re not making revenue — burning cash every quarter.
Stock is very volatile, thinly traded, and sensitive to technical flow.
📈 Market Sentiment & Valuation
Analyst consensus: Mostly Buy, though some are cautious.
Average 12-month target: $7–$9, which is much higher than current price (~$1.23).
Technicals: Mixed signals — short-term averages are favorable, but long-term trend is weak.
💡 My Take (Simple)
Upside potential is huge, if their clinical trials work out — this is a “bet on future” stock.
But risk is very high: bad trial news or cash burn could hurt badly.
Only consider as a speculative biotech play, not a stable investment